Indegene: Lean Tech, Strong Value

Indegene stands out because it does not look like a typical IT company. It serves life sciences firms with a mix of technology, analytics, and commercial services, and that model is helping it grow faster and work more efficiently than many peers. The latest numbers are strong. In Q1FY27, revenue rose 39.7% year-on-year to Rs 1,063.1 crore. The company also said revenue per employee hit about $77,100, up from roughly $50,000 to $55,000 four years ago. That is a big jump and shows better productivity. Earlier, in Q2FY25, revenue was Rs 686.8 crore, up 8% year-on-year, EBITDA was Rs 126.7 crore, and PAT was Rs 91.7 crore, with a PAT margin of 13.4%. For shareholders, this is clearly useful if the company can keep turning higher efficiency into higher earnings. A rising revenue per employee means the business is getting more output from each person, which can support margins and reduce dependence on hiring more staff. That is usually a positive sign in a tech-led services company. The upside is that Indegene has a niche market, strong client demand, and an operating model that benefits from AI, automation, and outcome-based delivery. If revenue keeps rising near the current pace and margins recover toward the 19% to 20% range management has guided for, shareholder value can improve meaningfully. But there is still a risk. Growth is good only if it is durable. If large clients delay spending, or if margin expansion fails to come through, the market may start questioning the valuation. A high-growth story can also become expensive very quickly, which can hurt returns if expectations are too high. Overall, Indegene looks beneficial for shareholders. It combines fast growth with strong productivity, and that is a rare mix. Still, investors should watch whether the company can sustain this pace without sacrificing profitability.